Study summary · research use only
[Effect of thymomimetic vilon on blood coagulation system and fibrinolisis in diabetes mellitus type 1 patients of different age]
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This human study examined patients with type 1 diabetes mellitus. The authors report that during destabilization patients showed accelerated blood coagulability, decreased natural anticoagulants (antithrombin III and protein C), increased fibrinogen and soluble fibrin-monomer complexes, and reduced fibrinolysis, which they interpreted as a chronic form of DIC syndrome. The abstract describes a correlation between the intensity of DIC syndrome and patient age, disease severity, insulin dose, and complications. Standard treatment was said not to considerably change intravascular coagulation, whereas administration of the thymomimetic peptide Vilon (Lys-Glu) was associated with reduced or diminished DIC syndrome. In elderly patients with severe disease, the reported action of Vilon on coagulative hemostasis and fibrinolytic activity was described as less pronounced. No numerical figures were given.
Abstract
It was revealed that patients suffering from the diabetes mellitus type 1 (DM-1) on the stage of destabilization report accelerated blood coagulability, decreased content of natural anticoagulators (antithrombin III and protein C), increased concentration of fibrogene and soluble fibrinmonomer complexes and reduced fibrinolysis. The obtained data testify the development of chronic form of DIC syndrome, moreover there is a correlation between the age of the patient, the severity of the disease, insulin dose, presence and severity of the complications on the one hand and the intensity of DIC syndrome on the other hand. Generally accepted treatment of the DM-1 patients doesn't exert considerable effect on the processes of intravascular blood coagulation. Meanwhile administration of thymomimetic Vilon (Lys-Glu) in these patients significantly reduces or even totally diminishes DIC syndrome. In elderly patients with severe form of the disease the effect of Vilon on coagulative hemostasis and blood fibrinolytic activity is less pronounced.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.